FLT180a for Hemophilia B Keeps Normal Factor IX Levels for 3+ Years

FLT180a for Hemophilia B Keeps Normal Factor IX Levels for 3+ Years

314791

FLT180a for Hemophilia B Keeps Normal Factor IX Levels for 3+ Years

In a Phase 1/2 dose-finding study called B-AMAZE, FLT180a gene therapy from Freeline Therapeutics brought about sustained levels of factor IX, the clotting factor that is missing in people with hemophilia B, and this translated into fewer bleeds each year. Levels of factor IX within the normal range were achieved with relatively low doses of FLT180a and maintained for more than three years. The results of the study, “Factor IX Expression within the Normal Range Prevents…

You must be logged in to read/download the full post.